Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma: Three cases and review of the literature

Yuko Isoyama, Yoshiyuki Shioyama, Satoshi Nomoto, Saiji Ohga, Takeshi Nonoshita, Kayoko Onishi, Shuji Matsuura, Kazushige Atsumi, Koutaro Terashima, Hideki Hirata, Hiroshi Honda

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose. Small-cell esophageal carcinoma (SCEC) is a rare disease for which standard therapy has not yet been established. We report the results of three cases of limited- stage SCEC treated with combination therapy using carboplatin (CBDCA) and etoposide (VP-16) and radiotherapy. Materials and methods. The clinical stage according to the Japanese Classifi cation of Esophageal Cancer 7th ed. was stage III in 2 cases and stage IVa in 1. These patients with limited-stage SCEC were treated at our institution with four cycles of CBDCA and VP-16, either concurrent with radiotherapy for the second two cycles (n = 2) or followed by radiotherapy after the last cycle (n = 1). Results. A complete response (CR) was obtained for all three patients, resulting in a response rate of 100%. Two patients are alive at 16.4 and 22.5 months after initial treatment. One patient died with myeloid leukemia at 43.5 months after initial treatment. None of the patients had loco-regional recurrence. Brain metastasis was detected in one patient at 7 months after initial therapy and was treated with stereotactic radiotherapy combined with whole brain irradiation. Conclusion. CBDCA and VP-16 in combination with radiotherapy should be considered an important treatment option for SCEC.

Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalJapanese Journal of Radiology
Volume28
Issue number3
DOIs
Publication statusPublished - Apr 1 2010

Fingerprint

Small Cell Carcinoma
Carboplatin
Etoposide
Radiotherapy
Therapeutics
Myeloid Leukemia
Brain
Esophageal Neoplasms
Rare Diseases
Cations
Neoplasm Metastasis
Recurrence

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma : Three cases and review of the literature. / Isoyama, Yuko; Shioyama, Yoshiyuki; Nomoto, Satoshi; Ohga, Saiji; Nonoshita, Takeshi; Onishi, Kayoko; Matsuura, Shuji; Atsumi, Kazushige; Terashima, Koutaro; Hirata, Hideki; Honda, Hiroshi.

In: Japanese Journal of Radiology, Vol. 28, No. 3, 01.04.2010, p. 181-187.

Research output: Contribution to journalArticle

Isoyama, Y, Shioyama, Y, Nomoto, S, Ohga, S, Nonoshita, T, Onishi, K, Matsuura, S, Atsumi, K, Terashima, K, Hirata, H & Honda, H 2010, 'Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma: Three cases and review of the literature', Japanese Journal of Radiology, vol. 28, no. 3, pp. 181-187. https://doi.org/10.1007/s11604-009-0403-7
Isoyama, Yuko ; Shioyama, Yoshiyuki ; Nomoto, Satoshi ; Ohga, Saiji ; Nonoshita, Takeshi ; Onishi, Kayoko ; Matsuura, Shuji ; Atsumi, Kazushige ; Terashima, Koutaro ; Hirata, Hideki ; Honda, Hiroshi. / Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma : Three cases and review of the literature. In: Japanese Journal of Radiology. 2010 ; Vol. 28, No. 3. pp. 181-187.
@article{0f49b79a68f046768dd68baad6199f33,
title = "Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma: Three cases and review of the literature",
abstract = "Purpose. Small-cell esophageal carcinoma (SCEC) is a rare disease for which standard therapy has not yet been established. We report the results of three cases of limited- stage SCEC treated with combination therapy using carboplatin (CBDCA) and etoposide (VP-16) and radiotherapy. Materials and methods. The clinical stage according to the Japanese Classifi cation of Esophageal Cancer 7th ed. was stage III in 2 cases and stage IVa in 1. These patients with limited-stage SCEC were treated at our institution with four cycles of CBDCA and VP-16, either concurrent with radiotherapy for the second two cycles (n = 2) or followed by radiotherapy after the last cycle (n = 1). Results. A complete response (CR) was obtained for all three patients, resulting in a response rate of 100{\%}. Two patients are alive at 16.4 and 22.5 months after initial treatment. One patient died with myeloid leukemia at 43.5 months after initial treatment. None of the patients had loco-regional recurrence. Brain metastasis was detected in one patient at 7 months after initial therapy and was treated with stereotactic radiotherapy combined with whole brain irradiation. Conclusion. CBDCA and VP-16 in combination with radiotherapy should be considered an important treatment option for SCEC.",
author = "Yuko Isoyama and Yoshiyuki Shioyama and Satoshi Nomoto and Saiji Ohga and Takeshi Nonoshita and Kayoko Onishi and Shuji Matsuura and Kazushige Atsumi and Koutaro Terashima and Hideki Hirata and Hiroshi Honda",
year = "2010",
month = "4",
day = "1",
doi = "10.1007/s11604-009-0403-7",
language = "English",
volume = "28",
pages = "181--187",
journal = "Japanese Journal of Radiology",
issn = "1867-1071",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Carboplatin and etoposide combined with radiotherapy for limited-stage small-cell esophageal carcinoma

T2 - Three cases and review of the literature

AU - Isoyama, Yuko

AU - Shioyama, Yoshiyuki

AU - Nomoto, Satoshi

AU - Ohga, Saiji

AU - Nonoshita, Takeshi

AU - Onishi, Kayoko

AU - Matsuura, Shuji

AU - Atsumi, Kazushige

AU - Terashima, Koutaro

AU - Hirata, Hideki

AU - Honda, Hiroshi

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Purpose. Small-cell esophageal carcinoma (SCEC) is a rare disease for which standard therapy has not yet been established. We report the results of three cases of limited- stage SCEC treated with combination therapy using carboplatin (CBDCA) and etoposide (VP-16) and radiotherapy. Materials and methods. The clinical stage according to the Japanese Classifi cation of Esophageal Cancer 7th ed. was stage III in 2 cases and stage IVa in 1. These patients with limited-stage SCEC were treated at our institution with four cycles of CBDCA and VP-16, either concurrent with radiotherapy for the second two cycles (n = 2) or followed by radiotherapy after the last cycle (n = 1). Results. A complete response (CR) was obtained for all three patients, resulting in a response rate of 100%. Two patients are alive at 16.4 and 22.5 months after initial treatment. One patient died with myeloid leukemia at 43.5 months after initial treatment. None of the patients had loco-regional recurrence. Brain metastasis was detected in one patient at 7 months after initial therapy and was treated with stereotactic radiotherapy combined with whole brain irradiation. Conclusion. CBDCA and VP-16 in combination with radiotherapy should be considered an important treatment option for SCEC.

AB - Purpose. Small-cell esophageal carcinoma (SCEC) is a rare disease for which standard therapy has not yet been established. We report the results of three cases of limited- stage SCEC treated with combination therapy using carboplatin (CBDCA) and etoposide (VP-16) and radiotherapy. Materials and methods. The clinical stage according to the Japanese Classifi cation of Esophageal Cancer 7th ed. was stage III in 2 cases and stage IVa in 1. These patients with limited-stage SCEC were treated at our institution with four cycles of CBDCA and VP-16, either concurrent with radiotherapy for the second two cycles (n = 2) or followed by radiotherapy after the last cycle (n = 1). Results. A complete response (CR) was obtained for all three patients, resulting in a response rate of 100%. Two patients are alive at 16.4 and 22.5 months after initial treatment. One patient died with myeloid leukemia at 43.5 months after initial treatment. None of the patients had loco-regional recurrence. Brain metastasis was detected in one patient at 7 months after initial therapy and was treated with stereotactic radiotherapy combined with whole brain irradiation. Conclusion. CBDCA and VP-16 in combination with radiotherapy should be considered an important treatment option for SCEC.

UR - http://www.scopus.com/inward/record.url?scp=77954568135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954568135&partnerID=8YFLogxK

U2 - 10.1007/s11604-009-0403-7

DO - 10.1007/s11604-009-0403-7

M3 - Article

C2 - 20437127

AN - SCOPUS:77954568135

VL - 28

SP - 181

EP - 187

JO - Japanese Journal of Radiology

JF - Japanese Journal of Radiology

SN - 1867-1071

IS - 3

ER -